Skip to main content

sildenafil

Generic: SILDENAFIL CITRATE·Brand: LIQREV, REVATIO, Revatio, SILDENAFIL CITRATE, VIAGRA, VYBRIQUE

sildenafil: sourced relationships with 2 companies · 4 clinical trials tracked · 4 FDA decisions.

sildenafil evidence translation

What we can confirm

4 FDA records · 4 tracked trials

What it means

More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

What is verified about sildenafil, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Birth Asphyxia

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
Teva Pharmaceutical Industries Limited (TEVA)
Reported 2016-03-09 · Current development: unknownSource
Approved
Viatris Inc (VTRS)
Reported 2009-11-18 · Current development: unknownSource
Approved
Clinical Trial Registry Records (4)

Efficacy of a Step-wise Protocol in Optimizing CCH Outcomes in Men With Peyronie's Disease

NCT06649539Registry updated 2026-08-26·Phase 4
Active, not recruiting

Primary endpoint: Penile Curvature

Interventionalopen40 targetStarted 2024-10Completion 2029-101 site · United StatesCharitable Union for the Research and Education of Peyronie's Disease

Finding Solutions to Thrive After Birth Asphyxia in Africa: An Open-label Dose-finding Clinical Trial (Phase Ib Study)

NCT05275725Registry updated 2026-09-15·Phase 1
Completed

Primary endpoint: Maximum tolerable dose of sildenafil

Interventionalopen18 enrolledStarted 2022-07Completion 2025-011 site · UgandaPia Wintermark

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

NCT04797286Registry updated 2026-09-28·Phase 2
Recruiting

Primary endpoint: Difference in change in distance walked in 6 minute walk test (6MWT) at 4 months

InterventionalRandomizedquadruple30 targetStarted 2021-09Completion 2026-112 sites · United StatesJohns Hopkins University

Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia: An Open-label Dose-finding Clinical Trial (Phase Ib Study)

NCT04169191Registry updated 2026-09-15·Phase 1
Completed

Primary endpoint: Death

Interventionalopen20 enrolledStarted 2019-09Completion 2025-101 site · CanadaMcGill University Health Centre/Research Institute of the McGill University Health Centre
FDA Decisions4 records
Approval(TEVA)FDA ↗
ANDA077342OralTablet
Approval(TEVA)FDA ↗
ANDA078380OralTablet
Approval1 INDICATIONS AND USAGE Adults REVATIO is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14) ] . Pediatric Patients (1 to 17 Years Old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise [see Clinical Studies (14) ] . Adults REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening. ( 1 ) Pediatric Patients (1 to 17 years old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standard exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise ( 1 , 14 )(VTRS)FDA ↗
NDA203109Type 3 - New Dosage FormOrphan DrugPriorityOralFor Suspension
Approval1 INDICATIONS AND USAGE Adults REVATIO is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14) ] . Pediatric Patients (1 to 17 Years Old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise [see Clinical Studies (14) ] . Adults REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening. ( 1 ) Pediatric Patients (1 to 17 years old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standard exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise ( 1 , 14 )(VTRS)FDA ↗
NDA022473Type 3 - New Dosage FormStandardIntravenousSolution

Frequently asked questions

Which companies have sourced relationships with sildenafil?

sildenafil has dated SEC/FDA relationship records for Teva Pharmaceutical Industries Limited, Viatris Inc.

How many clinical trials involve sildenafil?

BioSniper tracks 4 clinical trials involving sildenafil.

What is sildenafil's latest FDA decision?

The most recent tracked FDA decision for sildenafil is Approval, dated March 9, 2016.